Table 5.

Characteristics of incident patients at start of ESRD treatment in Norway and the United States regarding incidence rates, causes, treatment indications, and predialysis care (1995 to 1997)a

NorwayUnited States
WhiteBlackTotal
ESRD incidence (per million inhabitants/yr)b,c79222672285
    diabetes992231111
    hypertension204922261
    glomerulonephritis20357334
    cystic kidney diseases79118
Age (yr; mean)b,c62625760
Unable to ambulate or transfer (%)c,d9777
GFR (ml/min per 1.73 m2)b,c7.67.87.47.7
Predialysis care by a nephrologistd,e
    duration (mo; median)2313812
    duration (%; <4 mo)19283730
    ≥5 visits (%)73NANA41
Transplantation as first treatment (%)b,c11312
Arteriovenous fistula as first access (%)c,d32171417
Predialysis treatment with erythropoietin (%)c,d43262024
Hemoglobin (g/dl)c,d10.69.79.19.5
Albumin (g/L)c,d36323132
  • a NA, data not available.

  • b Source: Norwegian Renal Registry.

  • c Source: USRDS Registry.

  • d Source: Norwegian Renal Registry (data available only for patients who started renal replacement therapy in Nord-Trondelag County and Sør-Trondelag County, including St. Olavs Hospital, the regional tertiary care hospital).

  • e Source: USRDS/DMMS Wave 2, 1996 to 1997 (31) and CHOICE study, 1995 to 1998 (47).